Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 1 , Pages 56-63 , January 2010

Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status

  • G.D. Norata

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy
    • Center for the Study of Atherosclerosis, SISA Sez Reg Lomb, Bassini Hospital, Cinisello Balsamo, Italy
    • Corresponding Author InformationCorresponding author. Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy. Tel.: +39 0250318293; fax: +39 0250318386.
    • ,
  • I. Baragetti

      Affiliations

    • U.O. Nefrologia e Dialisi – Ospedale “E. Bassini” - Cinisello Balsamo, Azienda Ospedaliera San Gerardo di Monza, Italy
    • ,
  • S. Raselli

      Affiliations

    • Center for the Study of Atherosclerosis, SISA Sez Reg Lomb, Bassini Hospital, Cinisello Balsamo, Italy
    • ,
  • A. Stucchi

      Affiliations

    • U.O. Nefrologia e Dialisi – Ospedale “E. Bassini” - Cinisello Balsamo, Azienda Ospedaliera San Gerardo di Monza, Italy
    • ,
  • K. Garlaschelli

      Affiliations

    • Center for the Study of Atherosclerosis, SISA Sez Reg Lomb, Bassini Hospital, Cinisello Balsamo, Italy
    • ,
  • S. Vettoretti

      Affiliations

    • U.O. Nefrologia e Dialisi – Ospedale “E. Bassini” - Cinisello Balsamo, Azienda Ospedaliera San Gerardo di Monza, Italy
    • ,
  • G. Piloni

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy
    • ,
  • G. Buccianti

      Affiliations

    • ASPREMARE-Associazione Prevenzione e Terapie Malattie Renali, Milan, Italy
    • ,
  • A.L. Catapano

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy
    • Center for the Study of Atherosclerosis, SISA Sez Reg Lomb, Bassini Hospital, Cinisello Balsamo, Italy

Received 9 July 2008 ,Revised 22 September 2008 ,Accepted 29 January 2009.

References 

  1. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091–1098
  2. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98:1603–1608
  3. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–1656
  4. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors?. Nephrol Dial Transplant. 2000;15:454–457
  5. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005;20:129–134
  6. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:134–141
  7. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl. 2003;S98–S102
  8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83
  9. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476
  10. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–2606
  11. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003;35:2186–2189
  12. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant. 2007;22:171–178
  13. Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S, et al. Effect of the −420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med. 2007;262:104–112
  14. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke. 2006;37:1558–1561
  15. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156:279–284
  16. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, et al. Effect of the toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med. 2005;258:21–27
  17. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007;38:2844–2846
  18. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2007;193:321–327
  19. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;
  20. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008;114:361–374
  21. Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun. 2004;316:165–169
  22. Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J. 2006;53:745–752
  23. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F, et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int. 2004;66:46–50
  24. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int. 2007;71:1279–1286
  25. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, et al. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun. 2005;335:1254–1263
  26. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J. 2008;409:623–633
  27. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129:815–822

PII: S0939-4753(09)00030-1

doi: 10.1016/j.numecd.2009.01.011

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 1 , Pages 56-63 , January 2010

Article Tools

* Image Usage & Resolution